PRESENTATION
Q2 2021 — Results presentation
Q2 2021PDF · 20 pages1.8 MB
1 -- 1 of 20 -- 2nd Quarter 2021 Earnings Call July 21, 2021 -- 2 of 20 -- Cautionary Note on Forward-looking Statements 3 This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com. -- 3 of 20 -- Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation, and TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA includes technology licensed from Alkermes Pharma Ireland Limited, RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Infectious Diseases PREZCOBIX/ REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., has been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation, XARELTO co-developed with Bayer HealthCare AG, PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA licensed from BTG International Ltd., VELCADE developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX licensed from Genmab A/S, BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc., ERLEADA is licensed from Regents of California and Memorial Sloan Kettering, BCMA CAR-T licensed and developed in collaboration with Legend Biotech USA Inc., Legend Biotech Ireland Limited (“Legend”), niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, DuoBody platform licensed from Genmab relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by the BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: -- 4 of 20 -- Enterprise Highlights Sales Performance and Earnings Review Capital Allocation and Guidance Q&A 5 Agenda 1 2 3 4 Joseph J. Wolk Executive Vice President, Chief Financial Officer Chris DelOrefice Vice President, Investor Relations Ashley McEvoy Executive Vice President Worldwide Chairman, Medical Devices Thibaut Mongon Executive Vice President Worldwide Chairman, Consumer Health Jennifer Taubert Executive Vice President Worldwide Chairman, Pharmaceuticals -- 5 of 20 -- Regional Sales Results Q2 2021 Q2 2020 % CHANGE Reported Operational1 U.S. $11.9 $9.5 24.9% 24.9% Europe 5.7 4.1 39.5 28.6 Western Hemisphere (ex U.S.) 1.4 1.1 20.6 12.7 Asia-Pacific, Africa 4.4 3.6 21.0 14.8 International 11.4 8.8 29.5 20.9 Worldwide (WW) $23.3 $18.3 27.1% 23.0% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Note: Values may not add due to rounding 2nd Quarter 2021 Sales Dollars in Billions 6 -- 6 of 20 -- 48.5%; 44.9%1 Q2 2021 Q2 2020 $2.48 $1.67 2nd Quarter 2021 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 7 Sales Adjusted Earnings2 Adjusted EPS2 27.1%; 23.0%1 $23.3 $18.3 GAAP Earnings 73.1% $6.3 $3.6 49.0% Q2 2021 Q2 2020 GAAP EPS 72.8% $2.35 $1.36 Q2 2021 Q2 2021 Q2 2020 Q2 2020 Q2 2021 Q2 2020 $6.6 $4.4 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 7 of 20 -- OTC $1,307 Skin Health/Beauty $1,170 Oral Care $426 Baby Care $387 Women's Health $230 Wound Care/Other $216 $3,735 13.3%, 9.2% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – 2nd Quarter 2021 Strong growth across multiple franchises primarily due to market recovery 8 Key Drivers of Operational Performance1 OTC • Growth driven by U.S. Allergy Care seasonal incidence and ZYRTEC promotional campaigns, MOTRIN recovery in China, and Digestive Health driven by PEPCID and COVID-19 related health care professional recommendations for the hydration benefit offering (ORSL) Skin Health/ Beauty • Growth driven primarily by WW COVID-19 recovery in key markets and lapping prior year low stocking levels at U.S. retailers, as well as new product stocking primarily in NEUTROGENA and AVEENO partially offset by competitive pressures. OUS growth partially offset by divestitures Oral Care • Growth primarily due to strong OUS performance for LISTERINE mouthwash due to an accelerating category and increase in demand from continued successful promotional campaigns, partially offset by divestitures Baby Care • Growth driven by OUS strength in ASPAC eCommerce and successful promotional activities for JOHNSON'S and AVEENO aided by lapping of prior year negative COVID-19 impacts. U.S. growth partially offset by comparison to prior year COVID-19 demand surge Women’s Health • Growth driven by lapping prior year negative COVID-19 impact and innovation launches in O.B. and STAYFREE Wound Care/Other • Growth driven by category wide U.S. market growth with increased consumer behavior focus on preparedness and infection prevention, seasonal inventory builds and lapping prior year de-stocking Adjusted Operational Sales2: WW 10.0%, U.S. 13.0%, Int’l 7.4% Reported: WW 13.3%, U.S. 12.4%, Int’l 14.1% Operational1: WW 9.2%, U.S. 12.4%, Int’l 6.3% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 13.8%, 8.9% 13.9%, 9.0% 16.6%, 13.4% 8.6%, 5.0% 7.0%, 2.5% 16.2%, 12.9% -- 8 of 20 -- Key Drivers of Operational Performance1 Immunology • Growth driven by continued strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis, strength of TREMFYA in Psoriasis and uptake in Psoriatic Arthritis, and market/share gains in SIMPONI ARIA • REMICADE decline due to biosimilar competition Infectious Diseases • Growth driven by the contribution of the COVID-19 vaccine in the U.S. and EU • Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency Oncology • DARZALEX increase driven by continued strong market growth and share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020 • IMBRUVICA growth primarily driven by market and continued share leadership, partially offset by COVID-19 related market dynamics including continued delays in new patient starts as well as competitive pressures from novel oral agents • Continued strong global launch uptake of ERLEADA Cardiovascular/ Metabolism/ Other (CVM/Other) • Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition • INVOKANA/INVOKAMET decline due to continued share erosion • Growth in XARELTO driven by demand, partially offset by higher commercial access cost Pulmonary Hypertension (PH) • Growth driven by strong sales of OPSUMIT and UPTRAVI due to continued share gains and market growth Adjusted Operational Sales2: WW 14.1%, U.S. 12.1%, Int’l 16.8% Immunology $4,231 Infectious Diseases $1,028 Neuroscience $1,808 Oncology $3,535 CVM/Other $1,126 PH $870 $12,599 17.2%, 13.6% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – 2nd Quarter 2021 9 Reported: WW 17.2%, U.S. 12.2%, Int’l 23.7% Operational1: WW 13.6%, U.S. 12.2%, Int’l 15.4% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (5.0)%, (7.3)% 10.4%, 8.7% 26.7%, 21.5% 13.9%, 10.6% 17.1%, 12.8% 20.1%, 17.0% Above-market performance driven by double-digit growth in key products -- 9 of 20 -- Orthopaedics $2,227 Surgery $2,522 Vision $1,183 Interventional Solutions $1,046 $6,978 62.7%, 57.2% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – 2nd Quarter 2021 Growth primarily driven by COVID-19 related market recovery and innovation 10 Reported: WW 62.7%, U.S. 77.2%, Int’l 51.6% Operational1: WW 57.2%, U.S. 77.2%, Int’l 41.9% Key Drivers of Operational Performance1 Interventional Solutions • Market recovery and success of new products and commercial strategies continuing to enhance global leadership Orthopaedics • Hips: Growth reflects market recovery combined with continued strength of our portfolio including the ACTIS stem aided by enabling technologies – KINCISE and VELYS Hip Navigation • Trauma: Global market recovery and uptake of new products including Cannulated Compression Headless Screws and Advanced Nailing Systems • Knees: Growth primarily driven by procedure recovery • Spine, Sports & Other: Market recovery and new products (CONDUIT and VIPER Prime) driving growth • Spine: WW: ~+52%, U.S.: ~+70%, OUS: ~+33% Surgery • Advanced: • Endocutters: ~+40% Driven by market recovery, market expansion and new products offsetting competitive pressure in the U.S. • Biosurgery: ~+48% Market recovery and share expansion driven by success of newer products (VISTASEAL and SURGICEL POWDER) and Asia Pacific market expansion • Energy: ~+40% Primarily due to market recovery, new products and expansion within the China market, offsetting competitive pressures in the U.S. • General: Growth primarily driven by market recovery, continued strength of the Suture portfolio, changes in U.S. inventory levels in Wound Closure and a prior year unfavorable one-time price adjustment in the U.S. partially offset by the impact of the ASP divestiture Vision • Contact Lenses/Other: Growth driven primarily by market recovery, new products and channel inventory changes in the U.S. • Surgical: Growth primarily due to market recovery & uptake of recently launched products Adjusted Operational Sales2: WW 58.7%, U.S. 77.9%, Int’l 43.8% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 77.4%, 71.3% 70.1%, 66.0% 53.4%, 48.6% 62.6%, 56.0% -- 10 of 20 -- 2021 2020 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $23,312 100.0 $18,336 100.0 27.1 Cost of products sold 7,587 32.5 6,579 35.9 15.3 Gross Profit 15,725 67.5 11,757 64.1 33.8 Selling, marketing and administrative expenses 6,073 26.1 4,993 27.2 21.6 Research and development expense 3,394 14.6 2,707 14.8 25.4 In-process research and development - - 6 0.0 Interest (income) expense, net 28 0.1 26 0.2 Other (income) expense, net (488) (2.1) 24 0.1 Restructuring 56 0.2 61 0.3 Earnings before provision for taxes on income 6,662 28.6 3,940 21.5 69.1 Provision for taxes on income 384 1.7 314 1.7 22.3 Net Earnings $6,278 26.9 $3,626 19.8 73.1 - Net earnings per share (Diluted) $2.35 $1.36 72.8 Average shares outstanding (Diluted) 2,671.6 2,665.5 Effective tax rate 5.8% 8.0% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $7,776 33.4 $5,337 29.1 45.7 Net earnings $6,625 28.4 $4,446 24.2 49.0 Net earnings per share (Diluted) $2.48 $1.67 48.5 Effective tax rate 14.8% 16.7% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 11 2nd Quarter 2021 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 11 of 20 -- Adjusted Income Before Tax by Segment1 2nd Quarter 2021 12 Pharmaceutical Medical Devices Consumer Health Expenses Not Allocated to Segments 2Q 2021 2Q 2020 Pharmaceutical 39.6% 44.1% Medical Devices 28.6% 1.2% Consumer Health 27.8% 24.0% Total 33.4% 29.1% 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 7/21/2021 % to Sales 2021 2020 ($0.3) ($0.2) $5.3B $4.7 $0.8 $7.8B $5.0 $2.0 $1.0 2 $0.1 -- 12 of 20 -- Notable New Announcements in 2nd Quarter 20211 Pharmaceutical • Regulatory Decisions: – RYBREVANT (amivantamab-vmjw) Receives U.S. FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations – PONVORY (ponesimod) receives European Commission approval for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features – DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma – DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Receives U.S. FDA Approval for Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse2 • Regulatory Submission: – Janssen granted Breakthrough Therapy Designation from the U.S. FDA for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma – Janssen Submits Marketing Authorisation Application to the European Medicines Agency for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma – Janssen Submits New Drug Application to U.S. FDA for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients • Other: – Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa – Janssen Discontinues Collaboration and License Agreement with argenx for Cusatuzumab – Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response Medical Devices • Regulatory Decisions: – TECNIS SYNERGY and TECNIS SYNERGY TORIC II IOLS a Next Generation Treatment for Cataract Patients Received Regulatory Approval and Launched in the U.S. and Canada • Other – ETHICON expands Advanced Bipolar Energy Portfolio with Launch of ENSEAL X1 Curved Jaw Tissue Sealer Consumer Health • Other – Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA and AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene2 13 1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases 2 Subsequent to the quarter -- 13 of 20 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 14 of 20 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q2 2021 Cash and Marketable Securities $25 Debt ($33) Net Debt ($8) Free Cash Flow2 ~$8 Q2 2021: $3.4B invested in R&D $2.8B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of July 21, 2021 15 -- 15 of 20 -- 1 Non-GAAP measure; excludes acquisitions and divestitures 2 Non-GAAP measure; excludes the impact of translational currency 3 Euro Average Rate: July 2021 = $1.19; Euro Spot Rate: July 2021 = $1.18 Note: Percentages may be rounded. 16 July (Base Business) April Comments Adjusted Operational Sales1,2 9.5% - 10.5% 8.7% - 9.9% Tightening of the range and strong base performance Operational Sales2 $90.0B - $90.8B 9.0% – 10.0% $89.3B - $90.3B 8.2% – 9.4% Midpoint of 9.5% Estimated Reported Sales3 $91.3B - $92.1B 10.5% – 11.5% $90.6B - $91.6B 9.7% – 10.9% Midpoint of $91.7B or 11.0% FX $1.3B or 1.5% impact 2021 Revenue Guidance July (Incl. COVID-19 Vaccine) FY 2021 COVID-19 Vaccine Assumptions Adjusted Operational Sales1,2 12.5% - 13.5% Anticipate final not-for-profit price up to $8.00 per dose Operational Sales2 $92.5B - $93.3B 12.0% – 13.0% Expected Full Year Vaccine Sales of ~$2.5B Estimated Reported Sales3 $93.8B - $94.6B 13.5% – 14.5% More than ½ of FY revenue estimate likely to occur in 4th quarter -- 16 of 20 -- 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: July 2021 = $1.19; Euro Spot Rate: July 2021 = $1.18 Note: Percentages may be rounded. 17 July (Incl. COVID-19 Vaccine) April Comments Adjusted Operational Sales1,2 12.5% - 13.5% 8.7% - 9.9% Tightening of range, strong base performance, and COVID-19 vaccine contribution Operational Sales2 $92.5B - $93.3B 12.0% – 13.0% $89.3B - $90.3B 8.2% – 9.4% Midpoint of 12.5% Estimated Reported Sales3 $93.8B - $94.6B 13.5% – 14.5% $90.6B - $91.6B 9.7% – 10.9% Midpoint of $94.2B or 14.0% FX $1.3B or 1.5% impact Adjusted Pre-Tax Operating Margin4,5 Nearly 200 bps improvement >200 bps improvement Net Other Income4 $0.8 - $0.9 billion $0.6 - $0.7 billion Increased investment returns related to our employee benefit programs Net Interest Expense / (Income) $100 - $200 million $150 - $250 million Lowering based on 1H2021 trends Effective Tax Rate4 16.0% - 17.0% 16.5% - 17.5% Certain one-time benefits in first half 2021 Adjusted EPS (Operational)2,4 $9.50 - $9.60 18.4% - 19.6% $9.30 - $9.45 15.8% - 17.7% Tightening of range to $0.10 & increasing midpoint by $0.17 Adjusted EPS (Reported)3,4 $9.60 - $9.70 19.6% - 20.8% $9.42 - $9.57 17.3% - 19.2% Midpoint of $9.65 or 20.2% FX $0.10 or 1.2% impact 2021 P&L Guidance -- 17 of 20 -- Pharmaceutical 18 2nd Half 2021 Assumptions and Outlook Medical Devices Consumer Health • Ongoing focus on reaching patients through transformational innovation and anticipate delivering a 10th consecutive year of operational above-market growth • Comprehensive overview planned at our Business Review on November 18th of our robust pipeline, long-term growth outlook, and key enablers of market-leading success • Expect full year competitive growth versus the market driven by science- based, professionally endorsed brands • Continue meeting the needs of our consumers while maintaining an enhanced margin profile through our end-to-end profitability improvement program • Continued focus on execution, meaningful innovation, and market recovery will enable full year double- digit growth versus prior year and growth versus 2019 • Expanding access to high quality care by developing solutions utilizing digital capabilities, scientific evidence and fact-based data Segment Full Year Considerations Sales Phasing and Considerations Pharmaceutical Continued strong, above market performance • Anticipate more balanced quarter to quarter growth throughout 2nd half • Expect more than half of COVID-19 vaccine revenue likely to occur in the 4th quarter Medical Devices Double digit growth driven by procedure recovery and continued momentum from enhanced execution of new product introductions • Expect continued, but non-linear recovery across geographies and procedures • Pace of recovery will be influenced by factors such as patient willingness to seek care, health system capacity, insurance and unemployment rates, and rate of easing of mobility restrictions Consumer Health Continue to drive competitive market growth • Anticipate more normalized growth in the 2nd half as consumers return to typical usage patterns • OTC performance will be dependent on seasonality impacts Note: Fourth Quarter growth will be negatively impacted by additional 2020 selling days due to the 53rd week that will not be repeated in 2021 (Q4 2020: ~4pts of growth related to additional selling days) -- 18 of 20 -- Q&A Jennifer Taubert Executive Vice President Worldwide Chairman, Pharmaceuticals Executive Vice President Worldwide Chairman, Medical Devices Ashley McEvoy Joseph J. Wolk Executive Vice President, Chief Financial Officer Thibaut Mongon Executive Vice President Worldwide Chairman, Consumer Health -- 19 of 20 -- -- 20 of 20 --